Free Trial
NASDAQ:CCCC

C4 Therapeutics Q3 2023 Earnings Report

C4 Therapeutics logo
$1.99 -0.03 (-1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 -0.03 (-1.76%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

C4 Therapeutics Revenue Results

Actual Revenue
$11.07 million
Expected Revenue
$6.94 million
Beat/Miss
Beat by +$4.13 million
YoY Revenue Growth
N/A

C4 Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Wednesday, November 1, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

C4 Therapeutics' Q2 2025 earnings is scheduled for Wednesday, July 30, 2025, with a conference call scheduled on Thursday, July 31, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

C4 Therapeutics Earnings Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More C4 Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email.

About C4 Therapeutics

C4 Therapeutics (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies that harness the body’s natural protein homeostasis pathways. The company’s proprietary “Modular Assembly of Degraders” (MAD) platform enables the design of bifunctional molecules that selectively target disease-causing proteins for degradation, rather than merely inhibiting their activity. By leveraging structure-based drug design and advanced screening technologies, C4 Therapeutics aims to expand the range of druggable targets, with an initial focus on oncology and immunology.

The company’s pipeline features multiple programs in preclinical and early clinical development across oncology and inflammation. C4 Therapeutics has advanced protein degraders directed at bromodomain-containing proteins, kinases, and transcription factors that have historically proven difficult to address with conventional small molecules. Through a strategic collaboration with Sanofi initiated in 2019, C4 Therapeutics is advancing degraders targeting key oncology pathways and exploring additional partnerships to broaden the application of its platform. The company continues to initiate discovery alliances with pharmaceutical partners to accelerate the translation of novel degradation modalities into potential therapies.

Founded in 2015 and headquartered in Cambridge, Massachusetts, C4 Therapeutics was established by a team of experts in chemical biology, medicinal chemistry, and drug discovery. The company maintains state-of-the-art research laboratories in the Greater Boston area, positioning it within one of the world’s leading biotechnology hubs. C4 Therapeutics has since grown its capabilities to include integrated discovery, translational biology, and early clinical development functions, enabling seamless progression of its therapeutic candidates from concept to human studies.

C4 Therapeutics is led by President and Chief Executive Officer Gregory T. Verdine, a pioneer in chemical biology and targeted protein degradation, alongside a management team comprising seasoned industry professionals. Under their guidance, the company is committed to advancing its innovative portfolio of degrader molecules and forging strategic collaborations to address unmet medical needs. By combining proprietary science with a disciplined development strategy, C4 Therapeutics strives to deliver transformative therapies for patients worldwide.

View C4 Therapeutics Profile

More Earnings Resources from MarketBeat